News
Life Molecular Imaging Collaboration Agreement
15 April 2024, IXICO plc (AIM: IXI), London, UK, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials.
Imeka Collaboration Agreement
3 April 2024, IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces a collaboration agreement with IMEKA Solutions Inc. ("Imeka") to provide access to Imeka's suite of services for white matter1 imaging deployed in Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, amongst other CNS indications.
The impact of diversity on Alzheimer's disease clinical trial design
Lammert Albers, Chief Commercial Officer of the Global Alzheimer's Platform Foundation talks with John Dwyer, President of the foundation, and our Chief Scientific Officer, Robin Wolz about the impact of this study diversity on current and future research and the opportunities at hand at the upcoming CTAD Clinical Trials on Alzheimer's Disease 2023 conference in Boston.
Huntington’s Disease Image Harmonization Consortium secures new member and funding to complete large-scale analysis of brain changes using IXIQ.Ai
New York, NY / London, UK, July, 12th 2023; The Huntington’s Disease Imaging Harmonization (HD-IH) Consortium, founded last year to conduct an unprecedented harmonization analysis of more than 6,000 participant-visit magnetic resonance images (MRIs) acquired from over 2,000 research participants, has now completed the initial phase and secured the necessary funding commitment to complete the…
Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease
Published on: September 21, 2022 View the full News here; Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights.
Engagement in New Consortium in Huntington’s disease
Published on: 10th May 2022 View the full News here; Engagement in new consortium in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights. IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis.
IXICO hails the introduction of IXIQ.Ai, its new brain imaging technology
Published on Proactive: 14th Feb, 2022 The new platform has been developed and validated in collaboration with academic and pharma partners, the company said. IXICO said its next-generation brain imaging technology that is more sensitive, accurate and flexible than the current platform will be available for clinical trials from next month (March).
Going for growth: IXICO primed to solve the challenge of increased clinical trial complexity through AI advances
Article written by ShareBuyers Editorial Team originally published here As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of IXICO (IXI), the AIM-listed specialist in AI data analysis for the international clinical trial market which has seen its share price increase by 80% over the past six months.…
1-8 of 13 results